An ally against childhood pneumonia

June 18, 2013 by Pam Auchmutey

(Medical Xpress)—Since 2000, children born in the United States benefit from the research of Keith Klugman, who helped develop the pneumonia vaccine that is now part of their immunization regimen. As a result, invasive pneumococcal disease among young American children has decreased by nearly 80%.

Children are less fortunate in the developing world, where pneumonia claims 800,000 lives annually—more than any other childhood disease. Klugman has made it his life's work to reverse that trend.

When the South African native joined the Rollins School of Public Health in 2001, he was regarded as the world's leading expert on in pneumonia. Four years later, Klugman was named the William H. Foege Chair of Global Health, funded by the Hubert Foundation in honor of Foege's contributions to the field.

In 2003, the New England Journal of Medicine published the results of Klugman's landmark study that proved overwhelmingly that the had the potential to save the lives of thousands of HIV-positive and HIV-negative children. Since then, Klugman has pushed to make the vaccine available to children in Africa and Southeast Asia.

"One challenge in particular is developing the evidence to show that the vaccine, when implemented in routine immunizations, reduces children's deaths," says Klugman. "That is largely the focus of our current research at Rollins."

Klugman's team has begun to evaluate in rural South Africa by looking at the ecology of the pre- and post-vaccine. Ultimately, they expect their results to show that the vaccine protects children up to age 5 and interrupts to unvaccinated children and adults.

Bacteria resistance to vaccines remains an ever-present threat, leading Klugman and several collaborators to embark on the largest project ever to sequence the 20,000 pneumococcal genomes. Researchers will collect strains of the bacteria before and after the vaccine is rolled out in four countries in Africa and analyze existing strains in the United States, Asia, and South America. Through genetic sequencing of these strains, they hope to identify the genomic changes associated with bacterial escape from the .

Pneumonia is the leading cause of death for children globally. For several years, Keith Klugman, MD, has focused on ways to reduce deaths from pneumonia and determined the most effective way is through vaccination.

Klugman is leading the five-year study, funded by the Bill & Melinda Gates Foundation, in collaboration with the CDC, the University of Cambridge in England, the National Institute for Communicable Diseases at Wits University in South Africa, the Wellcome Trust Sanger Institute unit in Malawi, the Medical Research Council in Gambia, and the Kenya Medical Research Institute.

Earlier this year, the Gates Foundation tapped Klugman to serve six months as its senior adviser on pneumonia prevention. Students also benefit from his expertise. A conversation with Klugman led MD/PhD student Michael Mina to study how influenza vaccines may impact diseases caused by bacteria.

Mina remembers that first meeting. "Keith told me, 'I'm fairly confident that the influenza virus is responsible for most pneumococcal disease during flu season.' His comment stuck with me," says Mina. "He has this wonderful ability to think broadly about the different aspects of human biology and disease."

Explore further: Genome sequencing provides unprecedented insight into causes of pneumococcal disease

Related Stories

Genome sequencing provides unprecedented insight into causes of pneumococcal disease

May 5, 2013
A new study led by researchers from Harvard School of Public Health (HSPH) and the Wellcome Trust Sanger Institute in the UK has, for the first time, used genome sequencing technology to track the changes in a bacterial population ...

Pneumococcal rates plunge after widespread vaccination of infants

May 27, 2013
The number of young children contracting the most common strains of potentially fatal pneumococcal disease has plummeted 97% since the universal vaccination against this bacterial disease began in 2005, with unvaccinated ...

Newly identified antibodies may improve pneumonia vaccine design

September 22, 2011
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria. The findings, which could improve vaccines against pneumonia, appear ...

2009 H1N1 pandemic flu more damaging to lungs, opens opportunities for bacterial infection

September 19, 2011
Many of the people who died from the new strain of H1N1 influenza that broke out in 2009 were suffering from another infection as well: pneumonia. A new study to be published Tuesday, September 20 in the online journal mBio ...

Recommended for you

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...

Compounds in desert creosote bush could treat giardia and 'brain-eating' amoeba infections

August 15, 2017
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego and the University of Colorado Anschutz Medical Campus have found that compounds produced by the creosote bush, a ...

New malaria analysis method reveals disease severity in minutes

August 11, 2017
Left untreated, malaria can progress from being mild to severe—and potentially fatal—in 24 hours. So researchers at the University of British Columbia developed a method to quickly and sensitively assess the progression ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.